New drug duo tested for rare blood cancer
NCT ID NCT07007052
Summary
This study is testing a combination of two drugs, tagraxofusp and venetoclax, for adults newly diagnosed with a rare and aggressive blood cancer called BPDCN. The main goal is to see if this combination leads to a complete remission after three months of treatment. Depending on their response, participants may receive more treatment cycles, a stem cell transplant, or stop the study treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AMIENS - CH Amiens Picardie Site Sud
Amiens, 80054, France
-
ANGERS - CHU - Maladies du sang
Angers, 49933, France
-
AP-HP - Hôpital Necker
Paris, 75015, France
-
AP-HP- CRETEIL - CHU Henri Mondor
Créteil, 94000, France
-
APHP - HOPITAL COCHIN - Hématologie
Paris, 75014, France
-
APHP - Hôpital Saint-Louis - Hématologie adultes
Paris, 75010, France
-
ARGENTEUIL - Centre hospitalier Victor Dupouy
Argenteuil, France
-
AVIGNON - Centre Hospitalier
Avignon, 84000, France
-
BESANCON - Hôpital Jean Minjoz - Hématologie
Besançon, 25030, France
-
BORDEAUX - Hôpital Haut-Levêque
Pessac, 33600, France
-
CHU SAINT-ETIENNE - iCHUSE
Saint-Etienne, 42271, France
-
CLAMART - Hôpital d'Instruction des Armées de Percy
Clamart, 92140, France
-
Clermont-Ferrand - Chu Estaing
Clermont-Ferrand, 63000, France
-
Corbeil-Essonnes - Ch Sud Francilien
Corbeil-Essonnes, France
-
Grenoble CHU - Hématologie Clinique
Grenoble, 38043, France
-
LILLE CHU - Hôpital Claude Huriez
Lille, 59037, France
-
LYON HCL- Site Sud
Lyon, France
-
Limoges CHU
Limoges, France
-
MARSEILLE - Institut Paoli-Calmettes
Marseille, 13000, France
-
METZ - CHR Metz-Thionville
Metz, 57085, France
-
MULHOUSE GHRMSA - Hôpital E. Muller - Hématologie
Mulhouse, 68070, France
-
Montpellier - Chu Saint Eloi
Montpellier, France
-
NANCY - CHU de Brabois
Vandœuvre-lès-Nancy, 54500, France
-
NANTES - Hôpital Hôtel Dieu - Hématologie Clinique
Nantes, 44093, France
-
Nimes CHU
Nîmes, France
-
POITIERS - Hôpital La Milétrie - Hématologie Clinique
Poitiers, 86000, France
-
REIMS - Hôpital Robert Debré - Hématologie Clinique
Reims, 51100, France
-
RENNES - CHU Pontchaillou - Hématologie Clinique
Rennes, 35033, France
-
ROUEN - Centre Henri Becquerel - Service Hématologie Clinique
Rouen, 76038, France
-
Strasbourg - Institut de Cancerologie Strasbourg
Strasbourg, 67200, France
-
TOURS - Hôpital Bretonneau
Tours, 37000, France
-
Toulouse - IUCT Oncopole - Service d'Hématologie
Toulouse, France
-
VERSAILLES - Hôpital André Mignot
Versailles, France
-
Villejuif Igr - Gustave Roussy
Villejuif, 94804, France
Conditions
Explore the condition pages connected to this study.